

18 August 2023

TREATMENT OF INFLAMMATORY DISEASES

How many patients were treated with the following drugs for the following diseases in the 3 months between the start of May 2023 and the end of July 2023?

Please use the latest available 3 months if May to July is not available and specify which 3 months has been used. Please ignore any cells which have been blanked out.

| Drug Name | Plaque psoriasis | Crohn's Disease | Ulcerative colitis | Psoriatic arthritis | Ankylosing spondylitis (inc. axial spondylitis) | Rheumatoid arthritis |
|--------------------------|------------------|-----------------|--------------------|---------------------|---|----------------------|
| Adalimumab (Humira) | 26 | <5 | 0 | 135 | 70 | 26 |
| Adalimumab (Biosimilars) | 170 | 0 | 0 | 248 | 135 | 140 |
| Apremilast | 8 | | | 28 | | |
| Bimekizumab | 5 | | | | | |
| Brodalumab | 0 | | | | | |
| Certolizumab Pegol | 5 | | | 47 | 26 | 21 |
| Deucravacitinib | 0 | | | | | |
| Etanercept (Enbrel) | 0 | | | 25 | 15 | 29 |
| Etanercept (Biosimilars) | 8 | | | 107 | 52 | 82 |
| Guselkumab | 84 | | | 8 | | |
| Infliximab (Remicade) | <5 | 0 | 0 | 14 | 9 | <5 |
| Infliximab (Biosimilars) | <5 | <5 | 0 | 13 | 10 | <5 |
| Ixekizumab | 57 | | | 52 | 18 | |
| Risankizumab | 82 | 0 | | 0 | | |
| Secukinumab | 42 | | | 162 | 47 | |
| Tildrakizumab | 6 | | | | | |
| Ustekinumab | 73 | 0 | 0 | 7 | | |
| Upadacitinib | | 0 | 0 | 15 | 9 | 24 |
| Vedolizumab | | 0 | 0 | | | |

18 August 2023

| | | | | | |
|-------------|--|---|----|----|-----|
| Filgotinib | | 0 | | | <5 |
| Golimumab | | 0 | 54 | 24 | <5 |
| Mirikizumab | | 0 | | | |
| Ozanimod | | 0 | | | |
| Tofacitinib | | 0 | 5 | <5 | 5 |
| Abatacept | | | | | 106 |
| Baricitinib | | | | | 21 |
| Rituximab | | | | | 18 |
| Sarilumab | | | | | <5 |
| Tocilizumab | | | | | 66 |

How many patients were treated with the following drugs from the following departments (for any disease) in the 3 months between the start of May 2023 and the end of July 2023?

Please use the latest available 3 months if May to July is not available and specify which 3 months has been used.

| Drug Name | Dermatology | Gastroenterology | Rheumatology |
|--------------------------|-------------|------------------|--------------|
| Adalimumab (Humira) | 46 | | 398 |
| Adalimumab (Biosimilars) | 198 | | 772 |
| Apremilast | 8 | | 30 |
| Bimekizumab | 5 | | 0 |
| Brodalumab | 0 | | 0 |
| Certolizumab Pegol | 5 | | 1123 |
| Deucravacitinib | 0 | | 0 |
| Etanercept (Enbrel) | 0 | | 127 |
| Etanercept (Biosimilars) | 8 | | 344 |
| Guselkumab | 84 | | 8 |
| Infliximab (Remicade) | <5 | | 53 |
| Infliximab (Biosimilars) | 9 | | 45 |
| Ixekizumab | 57 | | 81 |
| Risankizumab | 83 | | <5 |
| Secukinumab | 43 | | 239 |
| Tildrakizumab | 6 | | 0 |
| Ustekinumab | 74 | | 14 |
| Upadacitinib | 15 | | 85 |
| Vedolizumab | 0 | | 0 |
| Filgotinib | 0 | | <5 |
| Golimumab | 0 | | 100 |
| Mirikizumab | 0 | | 0 |

18 August 2023

| | | | |
|-------------|----|--|-----|
| Ozanimod | 0 | | 0 |
| Tofacitinib | 0 | | 25 |
| Abatacept | <5 | | 265 |
| Baricitinib | <5 | | 45 |
| Rituximab | <5 | | 85 |
| Sarilumab | 0 | | <5 |
| Tocilizumab | 0 | | 198 |